文献速递心脑血管急症重症综合管理与镇静镇痛

动脉瘤性蛛网膜下腔出血临床研究中结局指标的系统评价

A Systematic Review of Outcome Measures Employed in Aneurysmal Subarachnoid Hemorrhage (aSAH) Clinical Research.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论系统评价发现aSAH随机试验结局指标高度异质(285种独特指标),GOS最常用但定义与时间点不一,支持制定核心结局集。

该系统评价检索Ovid Medline、EMBASE、CINAHL和CENTRAL,纳入1996年1月至2015年5月发表的aSAH随机临床试验,按OMERACT框架分类主要和次要结局。共纳入129项试验、24238例患者,识别出285种独特结局指标。GOS是最常用的主要结局(13/129,10.1%),死亡率报告于84项试验(65.1%),3个月是最常见时间点(34/129,26.4%);GOS(65/129,50.4%)和改良Rankin量表(51/129,39.5%)是最常用的功能指标,但报告时间点和二分界值不一。患者报告的生活质量指标仅用于11项试验(8.5%),经颅多普勒是最常用影像模态(40/129,31.0%)。结局指标的显著异质性支持为aSAH试验制定核心结局集。

要点

  • 129项aSAH随机试验共报告285种独特结局指标,结局选择高度异质。
  • GOS是最常用主要结局(13/129,10.1%),死亡率报告于84项试验(65.1%),3个月为最常见时间点(34/129,26.4%)。
  • 功能结局以GOS(65/129,50.4%)和改良Rankin量表(51/129,39.5%)最常用,但时间点和二分界值不一致。
  • 患者报告的生活质量指标仅用于11项试验(8.5%)。
  • 经颅多普勒是最常用影像模态(40/129,31.0%),血管痉挛、迟发性脑缺血和影像结果的报告定义高度可变。

适用人群与场景

  • 1996年1月至2015年5月发表的动脉瘤性蛛网膜下腔出血随机临床试验,共129项试验、24238例患者。

研究设计与关键结果

  • 系统评价共识别1093项潜在研究,129项符合纳入标准,代表24238例患者,报告285种独特结局指标。
  • GOS是最常用主要结局(13/129,10.1%);死亡率报告于84项试验(65.1%),3个月为最常见时间点(34/129,26.4%)。
  • GOS(65/129,50.4%)和改良Rankin量表(51/129,39.5%)是最常用功能指标,但报告时间点不同且常以不同范围二分。
  • 患者报告的生活质量指标用于11项试验(8.5%);经颅多普勒是最常用影像模态(40/129,31.0%)。
  • 血管痉挛、迟发性脑缺血和影像模态结果的定义与报告高度可变。

证据类型、等级与局限

  • 证据类型:系统评价。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为aSAH随机试验结局指标的显著异质性支持制定核心结局集(COS)。
  • 作者认为本研究识别了广泛范围的结局,可供未来aSAH核心结局集潜在纳入。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Consensus on appropriate outcome measures to use in aneurysmal subarachnoid hemorrhage (aSAH) research has not been established, although the transition toward a core outcome set (COS) would provide significant benefits. To inform COS development, we conducted a systematic review to identify outcome measures included in reports of randomized clinical trials (RCTs) of interventions in patients with aSAH. Ovid Medline, EMBASE, CINAHL, and CENTRAL were searched. RCTs investigating aSAH published between January 1996 and May 2015 were included. The primary and secondary outcomes of RCTs were recorded and classified according to the OMERACT Consortium's framework. We identified 1093 potential studies of which 129 met inclusion criteria representing 24 238 patients. There were 285 unique outcome measures. The Glasgow Outcome Scale (GOS) was the most frequently used primary outcome (13/129, 10.1%). Mortality was reported in 84 trials (65.1%) with 3 months the most common time point (34/129, 26.4%). The GOS (65/129, 50.4%) and the Modified Rankin Scale (51/129, 39.5%) were the most commonly reported functional measures; however, these were reported at different time points and often dichotomized using different ranges. Patient-reported quality of life measures were used in 11 trials (8.5%). Transcranial Doppler was the most frequently used imaging modality (40/129, 31.0%). Definitions and reporting of vasospasm, delayed cerebral ischemia and imaging modality results were highly variable. The marked heterogeneity of outcomes in reports of RCTs supports the development of a core outcome set for aSAH trials. Our study has identified a wide range of outcomes for potential inclusion in a future aSAH COS.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Andersen CR, Fitzgerald E, Delaney A, et al. A Systematic Review of Outcome Measures Employed in Aneurysmal Subarachnoid Hemorrhage (aSAH) Clinical Research. Neurocrit Care. 2019. PMID: 29951958. doi:10.1007/s12028-018-0566-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。